Kazia director granted 100,000 stock options
Kazia Therapeutics Ltd director Ebru Davidson received a board-approved grant of 100,000 employee stock options over ADSs.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Kazia Therapeutics Ltd director Ebru Davidson received a board-approved grant of 100,000 employee stock options over ADSs. The options carry an exercise price of $9.10 per ADS, were granted for no cash consideration, vest on January 8, 2027, and expire on January 8, 2029. Following this award, Davidson holds 100,000 derivative securities directly.
Insider Trade Summary
Grant/Award: 100,000 shares
Grant/Award
1 txn
Insider
Davidson Ebru
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Employee Stock Option (right to buy) | 100,000 | $0.00 | $0.00 |
Holdings After Transaction:
Employee Stock Option (right to buy) — 100,000 contracts (Direct)
Footnotes (1)
- F1. Represents a board-approved award of 100,000 options over ADSs, approved by the Remuneration Committee on January 8, 2026, at an exercise price of $9.10 per ADS. The exercise price for Australian resident participants reflects Australian tax considerations applicable to grants under the Issuer's employee share plan. The options vest on January 8, 2027. The options were granted for no consideration and expire on January 8, 2029.
Key Figures
Options granted: 100,000 options
Exercise price: $9.10 per ADS
Vesting date: January 8, 2027
+2 more
5 metrics
Options granted
100,000 options
Board-approved employee stock option award over ADSs
Exercise price
$9.10 per ADS
Exercise price for the granted options
Vesting date
January 8, 2027
Date when options vest and become exercisable
Expiration date
January 8, 2029
Date when unexercised options expire
Derivative holdings after transaction
100,000 options
Total options held following this grant
Key Terms
Employee Stock Option, ADSs, Remuneration Committee, exercise price
4 terms
Employee Stock Option financial
"Represents a board-approved award of 100,000 options over ADSs"
An employee stock option is a promise that lets a worker buy company shares later at a predetermined price, often after they stay for a certain period or meet performance goals — think of it like a coupon that locks in today's price for a future purchase. It matters to investors because options align employees’ incentives with company performance, can increase the number of shares outstanding (dilution) when exercised, and represent a compensation cost that affects reported profits and shareholder value.
ADSs financial
"Represents a board-approved award of 100,000 options over ADSs"
Remuneration Committee financial
"approved by the Remuneration Committee on January 8, 2026"
A remuneration committee is a group of independent board members who design, approve and oversee pay packages for a company’s executives and directors. Think of them as the household budget planners for top management: they decide salaries, bonuses and stock awards so pay rewards performance and limits excessive risk. For investors, their role matters because compensation policies affect management incentives, business strategy and the long‑term value shareholders receive.
exercise price financial
"at an exercise price of $9.10 per ADS"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Kazia Therapeutics (KZIA) director Ebru Davidson report on this Form 4?
Director Ebru Davidson reported receiving 100,000 employee stock options over ADSs. These were granted as a board-approved award, with no cash consideration paid, and are part of compensation rather than an open-market share purchase or sale.
What is the exercise price of the new Kazia Therapeutics (KZIA) stock options?
The granted options have an exercise price of $9.10 per ADS. The footnote notes that for Australian resident participants, this price reflects Australian tax considerations under the company’s employee share plan, defining the cost to exercise each option into one ADS.
When do Ebru Davidson’s Kazia Therapeutics (KZIA) options vest and expire?
The 100,000 options vest on January 8, 2027, meaning they become exercisable on that date. They expire on January 8, 2029, after which any unexercised options lapse and can no longer be converted into ADSs.
How many Kazia Therapeutics (KZIA) derivative securities does Ebru Davidson hold after this grant?
After the reported grant, Davidson’s total derivative holdings shown in this filing are 100,000 options. All of these relate to ADSs, with the Form 4 indicating the entire amount reflects this single compensation award of employee stock options.
Was cash paid for the Kazia Therapeutics (KZIA) option grant to Ebru Davidson?
No cash was paid for this grant. The footnote explains the 100,000 options over ADSs were granted for no consideration, consistent with standard equity-based compensation awards approved by the board and its Remuneration Committee.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates